{"id":"control-23-valent-ppv","safety":{"commonSideEffects":[{"rate":"20-50%","effect":"Injection site pain, erythema, or swelling"},{"rate":"5-15%","effect":"Fever"},{"rate":"5-10%","effect":"Myalgia or arthralgia"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Control 23-valent PPV (pneumococcal polysaccharide vaccine) contains purified capsular polysaccharides from 23 serotypes of Streptococcus pneumoniae. Upon vaccination, these polysaccharide antigens trigger B-cell responses and antibody production, primarily IgG antibodies, which bind to pneumococcal capsules and facilitate opsonization, complement activation, and phagocytic clearance of the bacteria. This provides immunological protection against invasive pneumococcal infections including pneumonia, bacteremia, and meningitis.","oneSentence":"This pneumococcal polysaccharide vaccine stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae, providing protection against pneumococcal disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:43:50.709Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of pneumococcal disease (pneumonia, bacteremia, meningitis) in adults and children ≥2 years of age"}]},"trialDetails":[{"nctId":"NCT05477693","phase":"PHASE4","title":"Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-10-25","conditions":"Pneumococcal Infections","enrollment":1800},{"nctId":"NCT04989465","phase":"PHASE4","title":"A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2021-09-10","conditions":"Pneumococcal Infections","enrollment":600},{"nctId":"NCT02451969","phase":"PHASE3","title":"Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults and Elderly","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2015-04","conditions":"Pneumococcal Infections","enrollment":1760}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":100,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Control 23-valent PPV","genericName":"Control 23-valent PPV","companyName":"Sinovac Biotech Co., Ltd","companyId":"sinovac-biotech-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"This pneumococcal polysaccharide vaccine stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae, providing protection against pneumococcal disease. Used for Prevention of pneumococcal disease (pneumonia, bacteremia, meningitis) in adults and children ≥2 years of age.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}